UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~October~~November 2022

Commission File Number: 001-38810

STEALTH BIOTHERAPEUTICS CORP

(Translation of registrant’s name into English)

Stealth BioTherapeutics Corp

c/o Intertrust Corporate Services (Cayman) Limited

One Nexus Way, Camana Bay

Grand Cayman

KY1-9005 Cayman Islands

(Address of principal executive ~~office~~offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

~~FORM~~ Form 20-F ☒ ~~FORM~~ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXHIBIT INDEX

Exhibit Number		Description
Exhibit No.		Description
99.1		Press Release -– Stealth BioTherapeutics Corp toAnnounces ~~Hold~~Completion ~~Extraordinary General Meeting~~ of ~~Shareholders~~Merger

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

~~STEALTH BIOTHERAPEUTICS CORP~~		STEALTH BIOTHERAPEUTICS CORP
By:	/s/ Irene P. McCarthy
Date: November 16, 2022		By:	/s/ Irene P. McCarthy
	Irene P. McCarthy
		Name:	Irene P. McCarthy
	~~Chief Executive Officer~~		Chief Executive Officer
Date: October 7, 2022

Filing Compare · Stealth BioTherapeutics Corp